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Abstract 
 
Introduction Accurate assessment of muscle insulin sensitivity requires measurement 
of insulin concentration in interstitial fluid (ISF), but has proved difficult.  We aimed to 
optimise measurement of ISF insulin concentrations in rat muscles in vivo using 
microdialysis.  
Methods Factorial experimental design experiments were performed in vitro to 
determine optimal conditions for insulin recovery with microdialysis probes.  These 
conditions were tested in vivo, adjusted appropriately and used in lean and obese Zucker 
rats to compare ISF insulin concentrations basally and during hyperinsulinaemic-
euglycaemic (HE) clamp.  
Results Optimal conditions in vivo were: a 100 kDa microdialysis probe inserted in 
muscle, perfused with 1% BSA, 1.5mM glucose in 0.9% sodium chloride at 1μl/min. 
Samples were collected into siliconised glass microvials. As a reference for insulin, we 
established a protocol of inulin infusion, beginning at -80min and reaching equilibrium 
within 60min.  HE clamp, beginning at 0min, increased ISF insulin concentration from 
122 ± 56  basally to 429 ± 180pmol/L (P < 0.05) in lean rats and from 643 ± 165 to 1087 
± 243pmol/L (P = 0.07) in obese rats; ISF insulin concentrations were significantly 
higher throughout in obese rats.  The difference between ISF and plasma insulin 
concentration (ISF:plasma ratio) was substantially higher in obese rats, but fell to 
similar values in obese and lean rats during HE clamp. 
Discussion Optimising insulin recovery with microdialysis allowed accurate 
measurement of basal ISF insulin in muscle of lean and obese Zucker rats and indicates 
insulin transport across capillaries is impaired in obese rats, basally and during 
hyperinsulinaemia. 
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Abbreviations: ISF; interstitial fluid, HE; hyperinsulinaemic-euglycaemic clamp, TET; 
transendothelial transport, BSA; bovine serum albumin, I/P ratio;  interstitial to plasma 
ratio, MI; insulin sensitivity, FEP; fluorinated ethylene propylene, ELISA; enzyme-linked 
immunosorbent assay, LBM; lean body mass, BW; body weight, MABP; mean arterial 
blood pressure, ABP; arterial blood pressure, BG; blood glucose, GIR; glucose infusion 
rate, HR; heart rate. 
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1 Introduction 
 
The prevalence of obesity and diabetes is increasing worldwide.  Thus, there is an 
associated need for accurate assessment of the factors that contribute to insulin 
sensitivity and resistance in animal models of these conditions.   Generally, insulin 
sensitivity of skeletal muscle, one of the major tissues for glucose disposal, is assessed 
from the relationship between plasma level of insulin and glucose uptake.  However, 
plasma insulin concentration is not a good index of the concentration of insulin in the 
interstitial fluid (ISF) of skeletal muscle from where it accesses insulin receptors on the 
sarcolemma.  Indeed, it is well established that the plasma insulin concentration 
required to increase glucose disposal rate in vivo is significantly higher than that 
required in vitro (Poulin, Steil, Moore, Ader, & Bergman, 1994).  Moreover, the rate of 
increase in glucose uptake during hyperinsulinaemic-euglycaemic (HE) clamp is delayed 
compared to the change in plasma insulin concentration (Castillo, Bogardus, Bergman, 
Thuillez, & Lillioja, 1994).  
 
The disparities between plasma and ISF insulin concentrations are partly explained by 
the fact that insulin must cross the capillaries in order to reach the ISF.  Trans-
endothelial transport (TET) of insulin is regulated by an insulin-receptor mediated 
process on the endothelial cells.  Insulin also acts on insulin receptors on resistance 
vessels and terminal arterioles to increase muscle blood flow and the capillary surface 
area for exchange (Barrett et al, 2009; 2011).  Thus, the relationship between plasma ISF 
and ISF insulin is dependent on the sensitivity of the insulin receptors at these different 
vascular sites and these factors in turn, affect estimates of muscle insulin sensitivity.  
Nevertheless, a full appreciation of the sensitivity of skeletal muscle to insulin ultimately 
requires that insulin concentrations be measured in ISF. 
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Insulin concentration in lymph has been used as a surrogate for ISF insulin 
concentration in hindlimb of humans (Castillo et al., 1994) and rats (Poulin et al., 1994).  
Such measurements indicated lymph concentrations are substantially lower than those 
in plasma and correlate better with glucose uptake than plasma insulin concentration 
(Yang, Hope, Ader, & Bergman, 1989).  However, lymph insulin concentration is not an 
accurate assessment of ISF insulin because lymph drainage from hindlimb derives from 
skin, adipose tissue and bone, as well as muscle.  The alternative is to use microdialysis 
to directly assay insulin in muscle ISF as has been reported in humans and rats (e.g. 
Sjostrand et al., 2000; Gudbjornsdottir, Sjostrand, Strindberg, & Lonnroth, 2005; 
Holmang, Mimura, Bjorntorp, & Lonnroth, 1997).  However, this is technically 
challenging particularly in rodents, because insulin is a large molecule that diffuses 
slowly across the pores of dialysis membranes, and because insulin concentration is 
notoriously difficult to measure in low concentrations in small fluid volumes.  Indeed, 
the low concentrations of insulin in ISF under basal conditions have not yet been 
measured accurately in the rat.  
 
Thus, the primary aims of the present study were to optimise the microdialysis 
methodology in vitro whilst employing validated techniques for assaying low 
concentrations of insulin in small fluid volumes.  We then adapted these techniques so 
that they could be used accurately and reliably to measure ISF insulin concentrations in 
vivo in the rat.  We also established than an inulin infusion given from 80min before the 
start of the experiment proper, could serve as an effective reference for insulin.  Our 
final aim was to measure ISF insulin concentration in hindlimb muscle of lean and obese 
Zucker rats in the basal state and during HE clamp so as to clarify the relationship 
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between plasma and ISF insulin and to allow direct estimates of skeletal muscle insulin 
sensitivity. 
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2  Methods 
 
2.1 Validation of the microdialysis method in vitro 
Factorial experimental design experiments were performed to determine the best 
conditions for recovery of insulin.  All equipment was purchased from CMA 
Microdialysis, Sweden via Linton Instrumentation, Norfolk, UK unless stated otherwise.  
 
2.1.1 Reagent preparation.  
All reagents were prepared on the day of study unless stated otherwise.  
Microdialysis perfusion fluid was prepared using 10% BSA and 20% (w/v) glucose.  A 
working solution of 1% BSA and 1.5mmol/L glucose was prepared in 0.9% sodium 
chloride and delivered at 1µl/min. 
Inulin A stock solution of 10mg/ml inulin was diluted in 0.9% sodium chloride to a 
solution concentration of 25µg/ml. 
Human insulin was prepared by diluting human insulin (Actrapid®, Novo Nordisk, 
Denmark) in 2% BSA (in 0.9% sodium chloride) to concentrations of 7000, 3000, 1000 
and 300pmol/L.  
 
2.1.2 Microdialysis probe preparation 
Microdialysis probes (CMA 20), 10mm in length with cut-off pore sizes of 55 or 100kDa, 
were connected via fluorinated ethylene propylene (FEP) tubing and tubing adapters.  
The inlet FEP tubing was connected to a 1ml microsyringe in an infusion pump (CMA 
402 dual syringe pump) filled with perfusion fluid (see above).  Insulin was diluted to 
7000pmol/L as detailed above and 1ml of solution was placed in siliconised glass vials. 
Glass vials were secured in a CMA 130 in vitro stand and microdialysis probes were 
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submerged in test solution and secured with the clips provided.  Probes were 
equilibrated for 40min with each new set of conditions.  The rate of perfusion was 1, 2 
or 2.5l/min.  All equipment and tubing was either treated with Sigmacote® (Sigma-
Aldrich Ltd, UK), or it was not.  Following initial experiments to test the optimum 
conditions for insulin recovery, further experiments were conducted to assess recovery 
at different concentrations of insulin (3000, 1000 and 300pmol/L) and inulin 
(25g/ml). 
 
2.1.3 Sample collection and analyses 
The perfusate was collected in either plastic, or glass vials: 40min samples were 
collected, split equally for storage and analysed in duplicate.  Insulin and inulin were 
assayed with ELISA Kits (see 2.2.7). 
 
2.2 Refinement of microdialysis methodology in vivo  
All experiments were conducted in accordance to the Animal Scientific Procedures Act 
1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments.  
They were performed on either male Wistar rats, or male lean or obese Zucker rats 
(supplied by Charles River, Kent, UK).  Anaesthesia was induced with an intra-peritoneal 
(i.p.) injection of 160-190mg/kg sodium-thiobutabarbitol (Inactin®, Sigma-Aldrich Ltd, 
UK) and supplemented as required, with bolus doses of 0.5ml, or by increasing the 
infusion rate of anaesthetic via a cannula placed in the jugular vein.  At the end of the 
experimental protocol, the animal was humanely killed by overdose of sodium-
thiobutabarbitol.  Death was confirmed by cervical dislocation. 
 
2.2.1 Experimental groups 
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2.2.1.1  Inulin infusion   
Experiments were performed on 3 anaesthetised male Wistar rats (weight 222 ± 15g) to 
establish whether inulin could be given by infusion so as to provide a reference for 
insulin.  The inulin infusion protocol was based on modelling of kinetics in preliminary 
experiments not reported here.  Thus, insulin was given as a 50mg/kg bolus followed by 
infusion at 2mg/kg/min for 180min.  Blood samples for analysis were taken at 1 and 
5min and then at 15min intervals.  Each sample was centrifuged at 13, 000RPM for 5min 
at 4oC and plasma was stored at 5oC and analysed <1week after collection.  In the 
preliminary inulin kinetic experiments, we tested whether samples could be frozen 
prior to analysis of inulin; these findings are shown in Supplementary Data Figure 1. 
 
2.2.1.2 Combined inulin infusion and HE clamp  
Experiments were performed on 4 male Wistar rats (weight 222 ± 15g); see 
Supplementary Data for details.  The methodology tested in these experiments was 
adopted for the experiments proper and is described in detail below (see 2.2.2 - 2.2.9).  
These experiments were also used to compare recovery of insulin with microdialysis 
probes at different pore cut-off sizes of 55 and 100kDa.  Therefore, half of the probes 
prepared and inserted as described in 2.2.4 and 2.2.5 were 55kDa and half were 100kDa.  
 
2.2.1.3 Use of validated microdialysis methodology during HE clamp  
Experiments were performed on 6 lean and 5 obese Zucker rats. Full methodology is 
described below (see2.2.2 – 2.2.9). 
 
2.2.2 Animal husbandry  
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Animals were housed in cages on a controlled 12 hour Light/Dark cycle, (6am: 6pm) and 
fed standard chow (SDS Rat and Mouse No. 1, 2.61 kcal/g of ration or 9.24% kcal of fat) 
and water ad libitum.  The day before the experiment proper, each rat received a fixed 
ration: 16 or 10g rat chow (obese and lean respectively) at 16:00 to provide sufficient 
food until approximately midnight.  Thus, the rat was non-absorptive, but not starved 
during the HE clamp protocol.  
 
2.2.3 Preparation of reagents  
All reagents were prepared on the day of study, unless otherwise indicated. 
Approximately, 80% of glucose uptake occurs in the skeletal muscle (Defronzo, 
Ferrannini, Sato, & Felig, 1981).  Thus, insulin sensitivity is expressed per fat-free mass 
(lean body mass; LBM) rather than body weight (Muniyappa, Lee, Chen, & Quon, 2008) 
and the HE clamp and inulin concentration were delivered according to LBM.  LBM was 
estimated from empirical linear regression formulae derived from body composition 
analysis of Zucker rats performed in-house.  The equations used for the Lean and Obese 
Zucker rat were LBM (g) = 31 + 0.77 x BW (g) and 59 + 0.50 x BW (g) respectively. 
 
Microdialysis perfusion fluid was prepared using 10 % BSA and 20 % (w/v) glucose. A 
working solution of 1 % BSA and 1.5mmol/L glucose was prepared in 0.9% sodium 
chloride and delivered at 1µl/min. 
Inulin A stock solution of 10mg/ml inulin was diluted in 0.9% sodium chloride so that 
we could deliver both a 1mg/kgLBM bolus and 0.08mg/kgLBM/min infusion.  The 
1mg/kgLBM bolus dose was given as 0.125ml bolus over 30 seconds.  The 0.08 
mg/kgLBM/min infusion was then given as 10µl/min for the rest of the experiment. 
Human insulin was prepared by diluting human insulin (Actrapid®, Novo Nordisk, 
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Denmark) in 10ml of Haemaccel®.  The volume of stock human insulin solution added to 
the Haemaccel® was determined according to the experimental group and lean body 
mass in kg, kgLBM.  The volume infusion rate was fixed in all experiments to 10µl/min. 
 
2.2.4 Microdialysis probe preparation 
Each probe (100kDa cut-off) was perfused in vitro prior to and during surgical 
preparation of the rat (>30min).  The probe inlet and outlet tubing was cut to 5cm and 
connected to siliconised ‘FEP’ tubing by using adapters.  The inlet tubing was connected 
to a 1ml microsyringe containing perfusion fluid.  The outlet tubing was cut to 45cm. 
The probes were placed in an in vitro stand and the syringe pump was started at 
1µl/min and allowed to run until probe insertion; perfusion fluid collected during this 
period was discarded.  
 
2.2.5 Surgical procedure and baseline measurements 
On the morning of the experiment proper, the rat was anaesthetised with an i.p. 
injection of 160-190mg/kg sodium-thiobutabarbitol as described in 2.2 above.  The right 
jugular vein was cannulated with five cannulae for infusions of insulin, glucose, inulin, 
and sodium-thiobutabarbitol.  The trachea was cannulated and medical O2 was directed 
over the opening at free flow to ensure adequate arterial oxygenation.  The left carotid 
artery was cannulated for blood sampling and recording of arterial blood pressure 
(ABP); mean ABP (MABP) was derived on-line.  All cannulae were filled with 20mM 
sodium citrate solution to prevent clotting.  Carotid artery catheter patency was 
maintained by continuous infusion (10μl/min) of 20mM sodium citrate solution.  Body 
temperature was monitored and maintained at 37°C using a rectal probe and heat 
blanket (Harvard Apparatus Ltd, UK).  
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Following surgery, the rat was allowed to stabilize for 40min from -120 to -80min (see 
Figure 1).  During this time, a microdialysis probe was inserted into the tibialis anterior 
muscle of both hindlimb at 45o to the skin surface by using a guide needle and split 
tubing.  It was tunnelled ~5mm under the surface of the skin parallel to the surface.  All 
tubing and equipment was siliconised on the basis of the in vitro studies (see Results).  
The outlet FEP tubing was fed into the refrigerated microfraction collector (CMA 470) 
set at 6oC and was positioned below the level of the rat.  The length of outlet tubing was 
calculated from the internal diameter to correspond to a 5 min time delay in the 
transport of each fraction collected from the rat to the siliconised glass microvial when 
perfusion was set at 1l/min, as determined by the in vitro measurements (see Results 
3.1). Each individual microdialysis probe used in vivo was calibrated for recovery of 
insulin as described in 2.2.8.  
 
A baseline arterial blood sample (200l) was taken at -90min from the carotid artery 
into potassium-EDTA coated tubes (Microvette®, Sarstedt Ltd., UK) and immediately 
centrifuged.  Plasma samples were split and stored at -20°C for later determination of 
insulin concentration, or at 4°C for determination of inulin concentration.  Additionally, 
a small drop of arterial blood was assayed for blood glucose by using a test strip (Roche 
Accu-chek®).   At -80min, infusion of inert inulin was commenced as a bolus (0.125ml) 
followed immediately by infusion at 10µl/min.  Collection by the microfraction collector 
was therefore started at -75min and a fraction was collected every 40min.  These 
fractions were directly correlated with plasma samples taken over the same periods, an 
additional arterial blood sample being taken at -60min to correspond with ISF Sample 1 
(Figure 1).  Microdialysis probes were checked regularly for patency and flushed at 
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20μl/min for ~ 30s if necessary.  Microdialysis probe placement was checked by 
dissection post mortem. 
 
2.2.6 Hyperinsulinaemic-euglycaemic clamp 
As shown in Figure 1, blood glucose concentration for the basal phase of the HE clamp 
was taken as the average of measurements taken at -20, -10 and 0min by using the test 
strips; each rat was clamped at the baseline blood glucose concentration for that particular 
rat so that there was no additional drive for endogenous insulin or counter-regulatory 
hormones other than what each rat strain experiences normally. Arterial blood samples 
(200l) for off-line analysis were collected via the carotid cannula at -20 and 0min.  
Sample 2 of ISF corresponded to the basal phase of the HE clamp.  The HE clamp phase 
began after collection of the 0min sample.  Human insulin was infused via the jugular 
vein using a digital syringe pump at 10μl/min.  The insulin concentration was calculated 
according to lean body mass (LBM, see above) and delivered at 10 and 20mU/kgLBM/min 
of insulin for lean and obese rats respectively.  Thereafter, arterial blood glucose 
concentrations were determined every 3 to 5min and blood glucose was clamped at the 
basal (euglycaemic) concentration for that particular rat by infusing glucose 20% (w/v) 
at a variable rate by using the digital syringe pump.  The infusion rate required to 
achieve this was noted so that glucose infusion rate (GIR) could be calculated and used 
to calculate insulin sensitivity (MI; see 2.2.8).  Additional arterial blood samples for 
analysis of glucose, insulin and inulin were taken at 20, 40, 60, 70 and 80min.  
 
2.2.7 Sample analysis   
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Plasma glucose was determined by using a Clinical Analyser, (YSI (UK) Ltd., Hampshire, 
UK).   Inulin concentration in the in vitro and in vivo studies was assayed by using the 
BioPal FIT-GFR kit (BioPal, Worcester, Massachusetts).  
 
In initial in vitro studies insulin was assayed with the Mercodia Ultrasensitive Rat 
Insulin Kit, which has a stated sensitivity range of 0.9-120pmol/L and should therefore 
detect concentrations lower than those detected by the Crystal Chem Rat Insulin ELISA 
kit (nominally 17.4 - 11,136pmol/L).  However, we established that the Mercodia kit 
could not be used with a volume less than the recommended 25l, which would have 
allowed only 2-3 samples to be assayed over the period of the HE clamp.  The Crystal 
Chem kit has the major advantage of only requiring a sample volume of 5l.  
Additionally, the Crystal Chem assay has been validated by the Analytical Group, CVGI, 
AstraZeneca, Alderley Park for the measurement of insulin in the range 5.4 - 
11,136pmol/L.  Insulin concentration in samples taken from the in vitro and in vivo 
studies were therefore analysed by using the same ultrasensitive rat insulin kit 
(Ultrasensitive Rat Insulin ELISA Kit, Crystal Chem, Illinois, USA).  As the ELISA kit used 
for insulin assay cross-reacts with the human insulin used for the HE clamp, two 
standard calibration curves were run on the ELISA plate, one using the rat insulin 
supplied in the kit and the other with human insulin spiked into rat plasma ISF.  Samples 
(plasma and ISF) before the initiation of insulin infusion were read off the rat standard 
curve and samples (plasma and ISF) collected after the initiation of insulin infusion were 
read off the human standard curve. (See Discussion for consideration of outcomes). 
 
For ISF sample collection, the outlet tubing volume was calculated using the internal 
diameter of the FEP tubing.  An outlet tubing length of 45cm was calculated to have a 
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volume of 5l and therefore to correspond to a 5min time delay from tissue to collection 
vial.  The CMA 470 Refrigerated microfraction collector was therefore started 5min after 
the inulin infusion and could then be taken to represent real time measurements of 
tissue concentrations, as the delay in the sample reaching the collection vial was 
accounted for.  The ISF Samples (microdialysate fractions of 40l collected over 40min 
in the microvials were split equally and stored at -80°C for later determination of 
insulin, or at 5°C for determination of inulin.  A 15µl sample of ISF was required in order 
that it could be diluted 1 in 10 to provide a large enough volume to test 50µl of diluted 
sample in duplicate with the BioPAL FIT-GFR (Inulin) kit.  A 15µl ISF sample was also 
required to test ISF samples neat on the Crystal Chem Rat Ultra Sensitive Insulin kit.  
Therefore, microdialysate fractions (40l) collected over 40min allowed for dead space 
and any small ultrafiltration of samples, whilst ensuring there was enough fluid volume 
for analysis of each fraction. 
 
2.2.8 Calculations 
2.2.8.1 Insulin Sensitivity (MI)  
MI was calculated as: 
 
MI (µmol/kg/min per pmol/L) = GIR (µmol/kg/min)/Plasma insulin (pmol/L) 
 
Where GIR is the steady state glucose infusion rate at the end of HE clamp and plasma 
insulin concentration represents measurements taken at corresponding time points.  
GIR was expressed as mg/kgLBM/min.  
 
2.2.8.2 Insulin recovery in vivo  
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ISF insulin concentration was calculated from the measured ISF insulin concentration in 
vivo, and adjusted per recovery of inulin in vivo by using the external reference 
technique (Jansson, Fowelin, Vonschenck, Smith, & Lonnroth, 1993) and the formula: 
 
Recovery of inulin in vitro/Recovery of insulin in vitro = Recovery of inulin in vivo/Recovery of insulin in vivo 
 
Thus, each insulin concentration was calculated using the corresponding inulin 
measurement from the same probe. ISF concentrations of insulin obtained from two 
probes, per rat, were averaged to obtain a mean measure for each rat. 
 
2.2.8.3 Interstitial to plasma (I:P) ratio.  This represents the ratio of insulin concentration 
between the circulation and ISF and was calculated as the ISF insulin concentration: 
plasma insulin concentration ratio. 
 
2.2.9 Statistical analysis 
Results are expressed as mean ± SEM unless otherwise indicated.  Differences between 
treatment groups were evaluated using an unpaired Student’s t-test.  Differences from 
baseline within the group were analysed using a one-way ANOVA with Dunnett’s post 
hoc test. 
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3. Results 
3.1  Validation of the microdialysis method in vitro  
Pore size. Experiments comparing pore size at 55 and 100kDa cut-offs showed that 
recovery of both insulin and inulin in vitro was higher with the 55kDa probe (see 
Supplemental Data Figure 3). 
Perfusion fluid. 1% BSA delivered at 1l/min consistently provided the highest recovery 
of insulin in each set of conditions, whereas 2% BSA at 2.5l/min consistently provided 
the lowest recovery in each set of conditions.  The optimal conditions for recovery were 
silicon-coated glass microvials with silicon-coated FEP tubing using perfusion fluid 
containing 1% BSA perfused at 1l/min (Figure 2).  These optimum conditions were 
then further tested at different concentrations of insulin and inulin to increase the 
accuracy of recovery calculations.  The in vitro recovery for insulin under these 
conditions was 9.4 ± 0.4% for 3000pmol/L, 14.7 ± 1.8% for 1000pmol/L and 3.2 ± 0.1% 
for 300pmol/L (n=2).  The in vitro recovery for inulin under these conditions was 16.7 ± 
5.2% for 25g/ml inulin (n=2).  Microdialysis perfusion fluid for all in vivo experiments 
was therefore prepared using 1% BSA with a fixed volume infusion rate of 1µl/min. 
 
3.2 Refinement of microdialysis methodology in vivo 
The pilot inulin infusion experiments showed that inulin infused from -80min achieved a 
stable level within 30 min that was maintained until cessation of infusion at 180min (see 
Supplementary Data Figure 2).  
 
The combined method validation experiments indicated that recovery of insulin in vivo 
was higher with a 100kDa MW cut-off probe than the 55kDa probe (3.07 ± 0.68 vs 1.35 ± 
0.10%; see Supplemental Data Figure 3).  
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3.3 Use of validated microdialysis methodology during HE clamp    
In experiments on lean and obese Zucker rats, inulin concentration reached steady state 
at -20min of the HE clamp (Supplemental Data Figure 3).  
 
3.3.1 Effects of HE clamp in lean and obese Zucker rats 
MABP was higher for obese rats throughout the protocol, whereas HR was not different 
between lean and obese rats. Neither variable changed during HE clamp (see 
Supplementary Data Figure 4).  
 
Blood glucose was significantly higher in obese, than lean rats throughout the protocol; 
neither group changed from baseline at any time point (see Figure 3A).  In obese rats, 
GIR was different from baseline from 24min onwards from the onset of the HE clamp, 
whereas in lean rats, GIR was increased from 13min onwards.  GIR was higher for lean 
than obese rats from 13min onwards (Figure 3B). 
 
Plasma insulin concentrations were significantly higher than their respective baseline at 
20 and 60min of the HE clamp in both lean and obese rats (Figure 4B; P < 0.05).  
 Plasma insulin concentration was significantly higher in obese, than lean rats 
throughout the protocol (Figure 4B).  Thus, insulin sensitivity (MI) calculated from GIR 
and plasma insulin was substantially higher in lean than obese rats:  (Supplemental Data 
Figure 5). 
 
The ISF insulin concentrations measured at the two baseline time points at an interval of 
40min were not different in either group (data not shown; P = 0.56 for obese and 0.35 
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for lean).  This indicated that trauma, inducing inflammation introduced by the insertion 
of the probe had stabilised by the time the HE clamp began.  Data from these two time 
points were therefore pooled to give one baseline value. 
 
During HE clamp, ISF concentration of insulin in lean rats increased from 66 ± 11pmol/L 
at baseline to 236 ± 53pmol/L (Figure 4A; P < 0.05) and stabilised at this level.  By 
contrast, ISF concentration of insulin in obese rats increased from 643 ± 165pmol/L at 
baseline to 1087 ± 243pmol/L during HE clamp (Figure 4 A, P = 0.07). The ISF 
concentration of insulin was higher in obese than lean rats under baseline conditions 
and at the end of HE clamp (Figure 4 A; P < 0.05).  The MI calculated from GIR and ISF 
insulin was substantially higher in lean than obese rats: 0.0266 ± 0.0019 vs. 0.0032 ± 
0.0012μmol/kg/min per pmol/L respectively. 
 
The I/P ratio of insulin was higher in lean rats than obese rats at baseline (Figure 4C; 
0.46 ± 0.04 vs. 0.23 ± 0.07, P < 0.05).  However, the I/P ratios decreased compared to 
baseline at 20 and 60min during the HE clamp in lean rats, while I/P fell modestly by 
20min in obese rats (Figure 4 C).  The I/P ratios were not different between lean and 
obese rats at 20 and 60min during the HE clamp.  
 
4 Discussion 
 
In this study we succeeded in making three novel contributions to the methodology 
required to measure skeletal muscle ISF insulin concentrations in healthy control rats 
and obese Zucker rats, a popular rat model of metabolic syndrome and type 2 diabetes. 
The first contribution is that we succeeded in scaling down the required volume of 
dialysate and concentration range of ISF to levels obtained in rat muscle ISF.  The second 
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and third contribution is that we succeeded in optimising the microdialysis 
methodology in vitro and in rat skeletal muscle in vivo.  We, therefore, have been able to 
measure for the first time, the concentrations of insulin in ISF of rat skeletal muscle 
under baseline conditions (overnight fasted) and during an HE clamp in both lean and 
obese Zucker rats.  Our results indicate that under baseline conditions, insulin 
concentrations in ISF were lower in lean than in obese Zucker rats and that the plasma 
insulin concentration was substantially higher in obese rats.  The baseline I/P insulin 
concentration ratio was much higher in lean than obese rats implying that transcapillary 
transport of insulin is impaired in the overnight fasted state in obese rats.  During the 
HE clamp ISF insulin increased markedly in lean rats, whereas the increase in ISF insulin 
in obese rats was modest despite a substantial, though not significant, increase in 
plasma insulin concentration.  As a result the I/P ratio became more similar between the 
lean and obese Zucker rats.   
 
4.1 Validation of the microdialysis methodology 
In order for microdialysis to be used effectively to assay ISF insulin particularly in small 
rodents, two major challenges had to be overcome.  Firstly insulin readily adheres to the 
types of material used for sample collection and assaying and secondly, insulin is very 
difficult to assay in concentrations in the pmol/L range in small volumes of <15l.  In the 
present study, we showed that recovery of insulin was greater under all conditions 
when the tubing and collection vials were siliconised with Sigmacote prior to use (Fig. 
2).  We tested two commercially available Ultra sensitive Insulin ELISA kits and 
established the Crystal Chem Ultrasensitive Rat Insulin ELISA kit was the most 
appropriate.  It can be used to assay insulin in small samples of 15l and will accurately 
detect insulin at concentrations as low as 5.4pmol/L, even though the manufacturer’s 
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stated range is 17.4-11,136pmol/L.  As the measurement of insulin is so vital to the 
accurate representation of the data and because the kit has a different affinity to rat and 
human insulin, two standard calibration curves were run on each ELISA plate, one using 
the rat insulin supplied in the kit and the other with human insulin spiked into rat 
plasma.  Hence, samples (plasma and ISF) before the initiation of insulin infusion were 
read off the rat standard curve and samples (plasma and ISF) collected after the 
initiation of insulin infusion were read off the human standard curve.  This is 
particularly important when comparisons are being made between concentrations of 
insulin measured under baseline and HE clamp conditions as it ensures that both rat and 
human insulin are measured as accurately as possible. 
 
We used the external reference technique to assess insulin recovery from ISF in vivo 
(Jansson et al, 1993) by using inulin because it has a molecular weight similar to insulin 
and passes between plasma and ISF by non-specific transcapillary diffusion (Chaurasia 
et al, 2007).   For the external reference technique to be accurate it is essential that the 
concentration of inulin in plasma and ISF has stabilised.  A novel aspect of the present 
study is that that we established that when inulin was given by infusion starting 80min 
before the HE clamp, a stable inulin concentration in plasma was achieved within 60min 
and was maintained throughout the HE clamp.  This simple addition to the protocol 
avoids the additional time and trauma to the animal caused by implanting an osmotic 
mini pump to deliver inulin as employed by others (Holmang et al., 1997).  
 
An important aspect of our in vitro studies was to test the available microdialysis probes 
and to explore the composition of the perfusion fluid.  Clearly, the pore size must be 
significantly larger than the molecule of interest in order to allow equilibration across 
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the membrane.  Probes with molecular weight cut-offs of 50kDa (Holmang, Niklason, 
Rippe, & Lonnroth, 2001; Holmang, Nilsson, Niklasson, Larsson, & Lonroth, 1999) or 
100kDa (Gudbjornsdottir, Sjostrand, Strindberg, Wahren, & Lonnroth, 2003; Sjostrand 
et al., 1999) have been used previously for measurement of insulin, but to date, they 
have not been compared.  The present experiments showed that in vitro, recovery of 
both insulin and inulin was higher with the 55kDa than 100kDa probe.  By contrast, in 
vivo, recovery of both insulin and inulin were better with the 100kDa MW cut-off probe.  
This may seem surprising because increased porosity of the dialysis membranes leads to 
increased internal hydraulic pressure caused by perfusion fluid entering the probe and 
this can cause ultrafiltration that works against the diffusion of insulin into the 
membrane.  Ultrafiltration also dilutes the microenvironment surrounding the probe 
leading potentially to under-estimation of the substance of interest (Chaurasia et al., 
2007).  However, we took steps to avoid ultrafiltration by ensuring the outlet tubing was 
below the level of the animal:  hydrostatic back pressure on the dialysis membrane 
causes ultrafiltration (Trickler and Miller (2003)).  Further, as air bubbles in the tubing 
may cause ultrafiltration when they reach the probe, we expelled them from the tubing 
before it was inserted into the tissue.  Due to the low flow rate of microdialysis fluid, we 
began flushing the tubing  >30min before the time of probe insertion into the rat 
anterior tibialis muscle .  
 
In previous studies it was shown that addition of an osmotic balancing agent such as 
dextran-70 or BSA (1-5%) to microdialysis perfusion fluid when using 100kDa or larger 
cut-off membranes prevented excessive ultrafiltration, by creating an osmotic pressure 
that offset the hydrostatic pressure.   Such colloids also helped prevent non-specific 
adsorption onto the materials of the device (Rosdahl et al., 2000; Trickler & Miller, 2003; 
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Gudbjornsdottir et al., 2005; Gudbjornsdottir et al., 2003; Holmang et al., 1997; Holmang 
et al., 2001; Holmang et al., 1999; Sjostrand et al., 1999; Sjostrand et al., 2000; Herkner 
et al., 2003).  In the present study, we found that addition of 1% BSA consistently 
provided the highest recovery of insulin in each set of conditions.  
 
The hydraulic pressure created by perfusion increases proportionally as flow rate is 
increased and thus, more fluid is lost from the probe at higher flow rates, particularly 
with probes of high molecular weight cut-off (Trickler & Miller, 2003).  Reducing the 
flow rate therefore reduces error and increases recovery (Lonnroth & Strindberg, 1995).  
Flow rates of 1, 2, or 2.5μl/min were used in previous studies to measure insulin in ISF 
(Holmang et al., 1999; Sjostrand et al., 1999; Holmang, Muller, Andersson, & Lonnroth, 
1998; Jansson et al., 1993).  In the present study, we established that 1% BSA delivered 
at 1l/min consistently provided the highest recovery of insulin in each condition.  
 
In view of these findings, perfusion fluid containing 1% BSA delivered at 1l/min was 
used for all experiments on lean and obese Zucker rats.  Although 7000pmol/L was the 
insulin concentration we routinely used to assess the optimum conditions for the 
measurement of insulin, we knew the concentration required might vary depending on 
the prevailing insulin concentration.  Recovery of insulin was therefore tested at insulin 
concentrations of 300, 3000 and 7000pmol/L corresponding to plasma insulin 
concentration in lean Zuckers under baseline conditions, obese Zuckers at baseline and 
lean Zuckers at HE clamp conditions and obese Zuckers during HE clamp respectively.  
This further increases the accuracy of the method.  As inulin concentrations in plasma 
were similar and constant in lean and obese rats, only one concentration of inulin was 
used for assessment of in vitro recovery. 
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4.2 Effects of HE clamp in lean and obese Zucker rats  
As expected, under baseline conditions, the obese rats were hyperglycaemic compared 
to the lean rats.  Both groups were fixed at euglycemia throughout the HE clamp as 
intended.  This was achieved by increasing GIR to higher levels in lean, than obese rats 
and the increase from baseline was required earlier in the lean rats.  As expected, 
plasma insulin concentrations were significantly lower in the lean than obese rats.  In 
fact, only during the steady state of the HE clamp did plasma insulin concentrations in 
lean rats reach the baseline concentration seen in the obese rats.  Thus, insulin 
sensitivity (MI) calculated from plasma insulin was ~8fold higher for lean, than obese 
rats.  
 
The insulin concentrations we measured in ISF were lower than plasma concentrations 
in lean rats under baseline conditions, indicating that the capillary bed acts as a 
functional barrier to the movement of insulin.  This is consistent with established 
evidence that an arterial-interstitial gradient exists for insulin (Sjostrand et al., 1999).  
Indeed, the only other study to measure baseline ISF insulin concentrations, – in healthy 
lean men rather than rats (Herkner et al., 2003) – also reported an insulin gradient: 48 ± 
8 pmol/L in plasma versus 19 ± 4 pmol/L in ISF under basal conditions.  Our finding that 
baseline concentrations of insulin in ISF in obese rats were significantly higher than in 
lean rats, but lower than in plasma, is novel and indicates that in obese rats also, the 
capillary bed acts as a functional barrier for transcapillary insulin transport.  However, 
as the I/P ratio was significantly lower in obese than in lean rats under baseline 
conditions (0.23 ± 0.07 vs. 0.46 ± 0.03) thus, it seems that the capillary transfer of 
insulin is blunted in obese rats even under baseline conditions.  
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The I/P ratio decreased from 0.65 ± 0.25 to 0.17 ± 0.07 in lean and from 0.23 ± 0.07 to 
0.11 ± 0.02 in obese rats during the HE clamp (by ~74% and ~52%, respectively) such 
that the I/P ratio in lean rats during HE clamp was similar to that of obese rats under 
basal conditions.  Similarly, Herkner et al., (2003) reported that in young men the I/P 
ratio decreased substantially from ~0.48 under basal conditions to ~0.12 during an HE 
clamp.  Interestingly, they found no change in the I/P ratio when plasma insulin reached 
the same peak value during the glucose tolerance test and concluded this reflects a 
transcapillary insulin transport mechanism that is partly saturable even during short-
term steady-state hyperinsulinaemia.  The new results of the current study suggest that 
transcapillary insulin transport might be closer to saturation in obese than in lean 
Zucker rats for they achieved a similar I/P ratio to that of lean rats at a much higher 
plasma concentration of insulin.  
 
In contrast to the present results, Holmang et al., (1997)  reported that during HE clamp 
at two different levels of hyperinsulinaemia, a plasma/ISF insulin gradient existed in 
lean Zucker rats, but not in obese Zucker rats.  They therefore concluded that 
transcapillary transport of insulin is not rate limiting for glucose metabolism in muscle 
of obese Zucker rats.  Their results are difficult to compare with the present findings not 
only because they made no measurements of ISF insulin under baseline conditions, but 
also because they used smaller (50kDa) molecular weight cut-off microdialysis probes, a 
less sensitive insulin assay and did not make allowances for cross-reactivity between 
human and rat insulin.  We suggest that the insulin concentrations we have estimated in 
the present study are more likely to be accurate than those of Holmang et al., (1997). 
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The relatively modest increase in ISF insulin we measured in the obese rats during HE 
clamp could be explained by an impaired insulin-induced dilatation of resistance and 
terminal arterioles and consequent blunted increase in muscle blood flow and 
recruitment of additional capillary surface area for transcapillary insulin transport, 
and/or by an impaired increase in TET of insulin (see Barrett et al, 2011; Wagenmakers 
et al, 2016).   Insulin causes dilatation by activating endothelial nitric oxide synthase 
(eNOS) via increased ser1177 phosphorylation (see Munyiappa et al, 2006), while NO-
induced nitrosylation of proteins is critically important for insulin-induced increase in 
TET (Wang et al, 2013). In related studies involving HE clamps comparable to those of 
the present study, we found that hindlimb muscle blood flow increased substantially in 
lean Zucker rats, but not in obese Zucker rats (Stride et al, 2012).  Further, HE clamp 
activated increased ser1177 phosphorylation of eNOS in terminal arterioles, but not 
capillaries of lean Zucker rats, whilst decreasing eNOS  ser1177 phosphorylation in 
terminal arterioles and capillaries of obese Zucker rats (Cocks et al, 2013).   Thus, it 
seems highly likely that the impaired transcapillary transport of insulin in obese Zucker 
rats during HE clamp is at least partly dependent on reduced ability of  arteriolar insulin 
receptors to induce dilatation (Wagenmakers et al, 2016).  Our results give no direct 
insight into differences in the insulin sensitivity of TET between lean and obese rats.   
However, if muscle insulin sensitivity estimated from GIR and ISF insulin concentrations 
rather than plasma ISF  (see Figures 3 and 4),  it seems the sensitivity is 15-fold greater 
in lean, than obese rats.  This suggests that a large part of the insulin resistance shown 
by obese Zucker rats is located at the level of the skeletal muscle fibres.    
 
Summary 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 27 
The present study allowed us to refine and validate the in vivo microdialysis 
methodology for determination of insulin concentration in the ISF of skeletal muscle in 
rats.  Notably, we established it is possible to quantify differences in ISF insulin 
concentration between lean and obese Zucker rats under basal concentrations.  Future 
studies will need to explore the broader validation of this approach in experimental 
animal models.  For instance, staggered microdialysis sampling combined with muscle 
blood flow recordings may allow further elucidation of the vascular and TET 
components of transcapillary insulin transport.  It would also be interesting to compare 
the effects of similar ISF concentrations of insulin in lean and obese rats on glucose 
uptake in the two strains. This would be expected to give a more accurate measure of 
insulin sensitivity.  
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Figure 1. Protocol used for the measurement of insulin with microdialysis during 
hyperinsulinaemic-euglycaemic clamp. Probe insertion was at -120 minutes. ISF samples were 
collected every 40 minutes from -120 minutes. Inulin infusion began at -80 minutes and continued 
throughout the protocol. HE clamp protocol started at 0 minutes and continued for 80 minutes. Insulin 
infusion was constant throughout the protocol. Glucose infusion was varied in order to maintain blood 
glucose concentration. Downward arrows represent plasma samples. 
Figure 2. FED analysis of in vitro recovery of insulin. FED analysis was completed to compare material 
of collection vial (glass or plastic), concentration of bovine serum albumin (1 or 2% BSA), rate of 
perfusion fluid (1, 2 or 2.5µl/min) and Sigmacote® treatment of equipment or not (Sigmacote®/No 
Sigmacote®). Bars represent the mean of two measurements taken under those conditions. 
Figure 3. Blood glucose concentration (BG) and glucose infusion rate (GIR) for 6 lean and 5 obese 
Zucker rats during hyperinsulinaemic euglycaemic clamp with microdialysis. Graphs show BG (A) 
and GIR (B). Symbols represent obese and lean groups (spherical black and square white, respectively). 
Values are mean ± SEM. † P < 0.05 obese versus lean control group. * P < 0.05 versus baseline. 
Figure 4. Plasma and interstitial insulin concentrations and the ratio between the two (I/P ratio) 
for 6 lean and 5 obese Zucker rats during hyperinsulinaemic euglycaemic clamp with 
microdialysis. Graphs show plasma (A) and interstitial (B) insulin concentrations and the I/P ratio (C). 
ISF insulin concentrations were measured from two microdialysis probes per animal and averaged to give 
a concentration value per animal. Symbols represent obese and lean groups (spherical black and square 
white, respectively). Values are mean ± SEM. † P < 0.05 obese versus lean control group. * P < 0.05 versus 
baseline.  
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